• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    RAPT Therapeutics, Inc. - Common Stock (NQ:RAPT)

    28.86 -0.18 (-0.62%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about RAPT Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 Next >
    Futures Slide As Bond Yields Jump To 6 Month High
    US stock futures and Treasuries dropped as muted trading resumed after the Christmas holiday, with investors looking to initial jobless claims data and a government bond auction later on Thursday. 
    Via Talk Markets
    Topics Bonds Commodities Cryptocurrencies
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
     
    Via Benzinga
    This Progressive Analyst Turns Bullish; Here Are Top 3 Upgrades For Thursday
     
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
     
    Via Benzinga
    Why RAPT Therapeutics Stock Gained Over 100% On Monday?
    RAPT Therapeutics partners with Shanghai Jemincare to develop RPT904, a potential alternative to Xolair, for food allergies. $35M upfront payment. 
    Via Benzinga
    US Stocks Mixed, Dow Tumbles 150 Points
     
    Via Benzinga
    Topics Stocks
    RAPT Therapeutics Announces $150 Million Private Placement
    From RAPT Therapeutics, Inc.
    Via GlobeNewswire
    RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody
    From RAPT Therapeutics, Inc.
    Via GlobeNewswire
    RAPT Therapeutics Reports Third Quarter 2024 Financial Results
    From RAPT Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's Pre-Market Session
     
    Via Benzinga
    Crude Oil Down 3%; Aramark Posts Upbeat Earnings
     
    Via Benzinga
    Nasdaq Moves Lower; Canaan Shares Surge
     
    Via Benzinga
    Rapt Therapeutics Stock Plummets, Terminates Asthma Trial Due To Patient's Liver Injury
    RAPT Therapeutics stock falls after halting its zelnecirnon program following FDA clinical hold. Company shifts focus. 
    Via Benzinga
    Dow Jumps Over 400 Points; Monday.com Shares Fall After Q3 Results
     
    Via Benzinga
    Topics Stocks
    Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury
    Continues to advance preclinical pipeline, including next generation CCR4 compounds, and pursue licensing opportunities 
    From RAPT Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's Intraday Session
     
    Via Benzinga
    10 Health Care Stocks Moving In Monday's Pre-Market Session
     
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Intraday Session
     
    Via Benzinga
    RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q2 2024
    RAPT stock results show that RAPT Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    RAPT Therapeutics Reports Second Quarter 2024 Financial Results
    From RAPT Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's After-Market Session
     
    Via Benzinga
    Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month
     
    Via Benzinga
    INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against RAPT Therapeutics, Inc. and Encourages Investors to Contact the Firm
    From Schall Law
    Via GlobeNewswire
    What's Going On With Dermatitis-Focused RAPT Therapeutics Stock On Thursday?
    RAPT Therapeutics closes Phase 2 trials for zelnecirnon in atopic dermatitis & asthma following FDA clinical hold due to liver failure. 
    Via Benzinga
    Why Duolingo Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
     
    Via Benzinga
    RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q1 2024
    RAPT stock results show that RAPT Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    12 Health Care Stocks Moving In Thursday's Intraday Session
     
    Via Benzinga
    RAPT Therapeutics Reports First Quarter 2024 Financial Results
    Company maintains solid cash position of $141.6 million 
    From RAPT Therapeutics, Inc.
    Via GlobeNewswire
    RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
    From RAPT Therapeutics, Inc.
    Via GlobeNewswire
    3 Biotech Stocks to Dump Before They Go to Zero
    These biotech stocks to sell are burning through cash at an alarming rate and seem destined for zero, making them prime targets for selling. 
    Via InvestorPlace
    < Previous 1 2 3 4 5 6 7 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.